A clinical study of imatinib in the treatment of advanced chordoma patients
QI Nan
DU Nan
WEI Xing
CHEN Bing-yao
LI Xiao-song
MA Jun-xun
FU Yan
ZHAO Hui
Abstract：Objective To study the clinical effects of advanced chordoma patients who were treated with oral imatinib. Methods From June 2007 to June 2012, 63 advanced chordoma patients who were admitted in our hospital were selected, including 24 cases with lost follow-up. The other 39 evaluable patients were followed up continuously. The platelet-derived growth factor receptor-β( PDGFR-β) protein expressions were detected pathologically before patients receiving imatinib treatment, and then they were divided into low and high expression groups. The dosage of oral imatinib for all the patients was 400 mg/d. The tumor growth was examined through CT or MRI every 3 months. The Response Evaluation Criteria in Solid Tumors ( RECIST ) was used to evaluate the clinical effects, and at the same time the differences in clinical effects of imatinib treatment between the 2 groups was compared. The Statistical Package for the Social Sciences Version 13.0 ( SPSS13.0 ) was used in statistical analysis, and P<0.05 meant that there were statistically signiifcant differences. The survival curve was drawn using the Kaplan-Meier method. Results Immunohistochemistry results were listed as follows. 25 patients had high expression of PDGFRβ, accounting for 64.1%. 14 patients had low expression of PDGFRβ, accounting for 35.9%. Among the 39 evaluable patients, no patients have complete response ( CR ), accounting for 0%, 3 patients with partial response ( PR ), accounting for 8%, 27 patients with stable diseases ( SD ), accounting for 69% and 9 patients with progressive diseases ( PD ), accounting for 23%. The clinical beneift rate was 76.9%( CR%+PR%+SD%). The median progression-free survival time was 9 months, and the median survival time was 31.2 months. The number of clinical beneifts was 22 in PDGFRβhigh expression group, and the clinical beneift rate was 88%. The number of clinical beneifts was 8 in PDGFRβlow expression group, and the clinical beneift rate was 57.1%. There were statistically signiifcant differences between the 2 groups, and the p value was 0.0282. Conclusions Our study further conifrms the anti-tumor activity of imatinib in advanced chordoma patients and good clinical beneifts. Meanwhile, better clinical effects can be achieved in PDGFRβhigh expression group.
Keywords：ChordomaImatinibTreatment outcomeProgram evaluation
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 110-114 )